Document Classification

Section Type: RESULTS

Text: As compared with placebo, palifermin was associated with significant reductions in the incidence of grade 4 oral mucositis (20 percent vs. 62 percent, P < 0. 001), patient-reported soreness of the mouth and throat (area-under-the-curve score, 29. 0 [range, 0 to 98] vs. 46. 8 [range, 0 to 110] ; P < 0. 001), the use of opioid analgesics (median, 212 mg of morphine equivalents [range, 0 to 9418] vs. 535 mg of morphine equivalents [range, 0 to 9418], P < 0. 001), and the incidence of use of total parenteral nutrition (31 percent vs. 55 percent, P < 0. 001).